Novel Therapeutic Targets of Solid Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (30 October 2024) | Viewed by 12848
Special Issue Editor
Interests: cancer; kinase inhibitor; target therapy; signal transduction; cell cycle; mitogenesis; survival; resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are proposing a Special Issue on “Novel Therapeutic Targets of Solid Cancer”.
Cancer is a complex genetic disease in which multiple pathways are involved in its development and progression. The identification of some key pathways of cancer pathogenesis is among the most spectacular achievements of modern biomedical science. Decades of research have helped to understand some of the underlying mechanisms, but our understanding of the disease is still incomplete. In recent years, technological advances such as various high-throughput omics methods have immensely helped unravel some of the unknown intricacies of cancer. The integration of data obtained from different omics methods has further facilitated the improvement of our knowledge. However, despite great progress, the dream of converting solid tumors into a chronic disease is still unsatisfied and long-term remission eludes us.
In recent years, the treatment of solid tumors has focused more on the personalization of treatment, progressively orienting itself towards what is called precision medicine. that is now considered a consolidated approach to cancer treatment and prevention. Indeed, for many types of cancer, molecular characterization of the tumor is the starting point for therapeutic decision-making. There are a few dozen well-validated targets in cancer cells, with a few hundred new drugs approved or in the final stages of clinical development. These therapies have revolutionized the treatment of lung, colorectal, breast, ovarian, skin and other cancers. Current advances in targeted therapy deserve in-depth discussion and are of considerable interest to a large readership.
This Special Issue of IJMS seeks to collect a series of original research articles and updated reviews that encompass all aspects of precision medicine through the identification of new targets in solid tumor oncology. Investigations in a myriad of fields such as biomarker discovery, "omics" approaches, such as pharmacogenomics, proteomics, genomics and transcriptomics are welcome. Work that helps decipher molecular changes and identify biomarkers and predictors of prognosis and behavior, as well as advances in therapeutic options and resistance mechanisms, are also topics of particular interest as are contributions on other significant topics that further enhance our understanding of molecular immunotherapy and all targeted cancer therapies.
Dr. Valentina De Falco
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- signal transduction
- kinase inhibitors
- targeted therapy
- precision medicine
- drug resistance
- survival
- cell cycle
- cell reprogramming
- stem cells
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.